<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24793028</PMID>
<DateCompleted>
<Year>2015</Year>
<Month>07</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1542-7714</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>12</Volume>
<Issue>11</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association</Title>
<ISOAbbreviation>Clin. Gastroenterol. Hepatol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis.</ArticleTitle>
<Pagination>
<MedlinePgn>1887-93.e3</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cgh.2014.03.035</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1542-3565(14)00635-1</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="OBJECTIVE">Among patients with quiescent ulcerative colitis (UC), lower fecal concentrations of calprotectin are associated with lower rates of relapse. We performed an open-label, randomized controlled trial to investigate whether increasing doses of mesalamine reduce concentrations of fecal calprotectin (FC) in patients with quiescent UC.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We screened 119 patients with UC in remission on the basis of Simple Clinical Colitis Activity Index scores, FC &gt;50 μg/g, and intake of no more than 3 g/day mesalamine. Participants taking mesalamine formulations other than multimatrix mesalamine were switched to multimatrix mesalamine (2.4 g/day) for 6 weeks; 52 participants were then randomly assigned (1:1) to a group that continued its current dose of mesalamine (controls, n = 26) or a group that increased its dose by 2.4 g/day for 6 weeks (n = 26). The primary outcome was continued remission with FC &lt;50 μg/g. Secondary outcomes were continued remission with FC &lt;100 μg/g or &lt;200 μg/g (among patients with pre-randomization values above these levels).</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The primary outcome was achieved by 3.8% of controls and 26.9% of the dose escalation group (P = .0496). More patients in the dose escalation group reduced FC to below 100 μg/g (P = .04) and 200 μg/g (P = .005). Among the patients who were still in remission after the randomization phase, clinical relapse occurred sooner in patients with FC &gt;200 μg/g compared with those with FC &lt;200 μg/g (P = .01).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Among patients with quiescent UC and increased levels of FC, increasing the dose of mesalamine by 2.4 g/day reduced fecal concentrations of calprotectin to those associated with lower rates of relapse. Clinicaltrials.gov number: NCT00652145.</AbstractText>
<CopyrightInformation>Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Osterman</LastName>
<ForeName>Mark T</ForeName>
<Initials>MT</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Aberra</LastName>
<ForeName>Faten N</ForeName>
<Initials>FN</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cross</LastName>
<ForeName>Raymond</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Liakos</LastName>
<ForeName>Steven</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>South Jersey Gastroenterology, Marlton, New Jersey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>McCabe</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Minnesota Gastroenterology, Bloomington, Minnesota.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shafran</LastName>
<ForeName>Ira</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Shafran Gastroenterology Center, Winter Park, Florida.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wolf</LastName>
<ForeName>Douglas</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Atlanta Gastroenterology Associates, Atlanta, Georgia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hardi</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Chevy Chase Clinic Research and George Washington University Medical School, Washington, District of Columbia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nessel</LastName>
<ForeName>Lisa</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Brensinger</LastName>
<ForeName>Colleen</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gilroy</LastName>
<ForeName>Erin</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lewis</LastName>
<ForeName>James D</ForeName>
<Initials>JD</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: lewisjd@mail.med.upenn.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<CollectiveName>DEAR Investigators</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList>
<AccessionNumber>NCT00652145</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>K24 DK078228</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K24-DK-078228-02S1</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K24-DK078228</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>04</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Clin Gastroenterol Hepatol</MedlineTA>
<NlmUniqueID>101160775</NlmUniqueID>
<ISSNLinking>1542-3565</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D039841">Leukocyte L1 Antigen Complex</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>4Q81I59GXC</RegistryNumber>
<NameOfSubstance UI="D019804">Mesalamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Clin Gastroenterol Hepatol. 2014 Nov;12(11):1894-6</RefSource>
<PMID Version="1">24951843</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003093">Colitis, Ulcerative</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005243">Feces</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D039841">Leukocyte L1 Antigen Complex</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019804">Mesalamine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">5 Aminosalicylate</Keyword>
<Keyword MajorTopicYN="N">5-ASA</Keyword>
<Keyword MajorTopicYN="N">Biomarker</Keyword>
<Keyword MajorTopicYN="N">MMX</Keyword>
<Keyword MajorTopicYN="N">Natural History</Keyword>
</KeywordList>
<InvestigatorList>
<Investigator ValidYN="Y">
<LastName>Lewis</LastName>
<ForeName>James D</ForeName>
<Initials>JD</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Cross</LastName>
<ForeName>Raymond</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Shah</LastName>
<ForeName>Samir</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Wolf</LastName>
<ForeName>Douglas</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>McCabe</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Liakos</LastName>
<ForeName>Steven</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Chasen</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Persky</LastName>
<ForeName>Seth</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Katz</LastName>
<ForeName>Seymour</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Shafran</LastName>
<ForeName>Ira</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Phillips</LastName>
<ForeName>Raymond</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Geenan</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Sherman</LastName>
<ForeName>Alex</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Hardi</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
</Investigator>
</InvestigatorList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2014</Year>
<Month>03</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2014</Year>
<Month>03</Month>
<Day>31</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2014</Year>
<Month>5</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2014</Year>
<Month>5</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2015</Year>
<Month>7</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">24793028</ArticleId>
<ArticleId IdType="pii">S1542-3565(14)00635-1</ArticleId>
<ArticleId IdType="doi">10.1016/j.cgh.2014.03.035</ArticleId>
<ArticleId IdType="pmc">PMC4214893</ArticleId>
<ArticleId IdType="mid">NIHMS591644</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Can J Gastroenterol. 2007 Dec;21(12):827-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18080055</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gastroenterology. 2007 Aug;133(2):412-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17681162</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Inflamm Bowel Dis. 2009 Jan;15(1):1-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18671232</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gastroenterology. 2009 Dec;137(6):1934-43.e1-3</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19766640</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aliment Pharmacol Ther. 2011 Mar;33(6):672-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21255059</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gastroenterology. 2011 May;140(6):1817-1826.e2</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21530748</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Crohns Colitis. 2012 Jun;6(5):557-62</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22398050</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Inflamm Bowel Dis. 2012 Oct;18(10):1894-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22238138</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Inflamm Bowel Dis. 2012 Nov;18(11):2011-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22223566</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gastroenterology. 2013 Jul;145(1):149-157.e2</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23528626</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Inflamm Bowel Dis. 2013 Aug;19(9):2031-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23811638</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Inflamm Bowel Dis. 2013 Sep;19(10):2111-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23883959</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aliment Pharmacol Ther. 2008 Jun 1;27(11):1094-102</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18363894</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gut. 1998 Jul;43(1):29-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9771402</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Gastroenterol. 2005 Nov;100(11):2478-85</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16279903</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gastroenterology. 2007 Feb;132(2):516-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17258720</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>